



(51) International Patent Classification:

C07D 417/14 (2006.01) **A61K 31/4439** (2006.01)
A61K 31/427 (2006.01) **A61P 31/04** (2006.01)

(21) International Application Number:

PCT/IB2011/055104

(22) International Filing Date:

15 November 2011 (15.11.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/417,575 29 November 2010 (29.11.2010) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, Matthew, Frank** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **MITTON-FRY, Mark. J.** [US/US]; 1375 North Street, Granville, Ohio 43023 (US). **HAN, Seungil** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **LALL, Manjinder** [CA/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **PLUMMER, Mark, Stephen** [US/US]; 6 Halls Road, Westbrook, Connecticut 06498 (US). **RISLEY, Hud, Lawrence** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **SHANMUGASUNDARAM, Veerabahu** [IN/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **STARR, Jeremy, T.** [US/US]; Pfizer Global Research and Develop-

ment, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: MONOBACTAMS

(57) Abstract: The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

